skip to main content, skip to Quick links, or skip to Search

main content

Canine Nerve Growth Factor Study

yellow lab face with activity monitor on red collar looking up

Evaluation of the Pain Alleviating Effects of NV-01 in Dogs Suffering from Osteoarthritis-Associated Pain

RECRUITMENT CLOSED

We are seeking participants for a trial of a new biological compound, an antibody, that is being used to treat pain. It is a canine version of a compound being tested for arthritis pain control in humans. The medication is NOT a non-steroidal anti-inflammatory (NSAID), and will administered twice subcutaneously with an expected duration of effect of several weeks.

Description: The purpose of this study is to evaluate the efficacy of NV-01, an antibody to nerve growth factor antibody, for the treatment of osteoarthritis pain in dogs. This is a blinded, placebo controlled, pilot study. Twenty four dogs will be recruited into this study. Each dog will be evaluated over a 16-week period for changes in pain and mobility using various owner assessments, activity monitors, kinetic variables and veterinarian-assessed joint pain.

Eligibility:

Dogs must satisfy the following criteria:

Dogs with the following conditions will be excluded:

Owner obligations:

We need owners of dogs to be able to commit to the following:

Study incentives: The study will cover the cost of the examination, hospitalization, blood work and urinalysis, radiographs, and study drug. No other financial incentives are offered for participation. 

 

Contact:
Comparative Pain Research Laboratory at North Carolina State University, College of Veterinary Medicine (919) 513-6853 or email beth_case@ncsu.edu

.